Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Why anti-Bcl-2 clinical trials fail: a solution

14 Dec 2013

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Galectins and Cancer Biology
Share to Toxin Mechanisms and Immunotoxins

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 24338002
DOI: 10.1007/s10555-013-9450-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Why anti-Bcl-2 clinical trials fail: a solutionPMID 24338002Read ↗

Thirty years of BCL-2: translating cell death discoveries into novel cancer therapiesSemantic proximity Read ↗

Breaking through BCL-2 inhibition in CLL.Semantic proximity Read ↗

Attacking cancer's Achilles heel: antagonism of anti‐apoptotic <scp>BCL</scp>‐2 family membersSemantic proximity Read ↗

Why G3139 works poorly in cancer trials but might work well against HIV.Semantic proximity Read ↗

The BCL-2 protein family: from discovery to drug developmentSemantic proximity Read ↗

BCL-2 in the crosshairs: tipping the balance of life and deathSemantic proximity Read ↗

Decoding and unlocking the BCL-2 dependency of cancer cellsSemantic proximity Read ↗

Mechanisms of venetoclax resistance and solutionsSemantic proximity Read ↗

BCL2 and miR-15/16: from gene discovery to treatmentSemantic proximity Read ↗

Drugging the p53 pathway: understanding the route to clinical efficacySemantic proximity Read ↗

Killing a cancer: what are the alternatives?Semantic proximity Read ↗

Development of PARP inhibitors: an unfinished story.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.